Research programme: caspase modulators - Molecumetics/Pharmacia

Drug Profile

Research programme: caspase modulators - Molecumetics/Pharmacia

Alternative Names: Caspase modulators research programme - Molecumetics/Pharmacia; Caspase stimulators research programme - Molecumetics/Pharmacia; Research programme: caspase stimulators - Molecumetics/Pharmacia

Latest Information Update: 14 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecumetics
  • Developer Molecumetics; Pharmacia Corporation
  • Class
  • Mechanism of Action Apoptosis inhibitors; Apoptosis stimulants; Caspase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Neurological disorders

Most Recent Events

  • 05 Apr 2000 Pharmacia & Upjohn merged with Monsanto to form Pharmacia Corporation
  • 05 Oct 1999 Preclinical development for Cancer in USA (Unknown route)
  • 05 Oct 1999 Preclinical development for Neurological disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top